儿童甲状腺功能亢进症二十年管理趋势与结局
该回顾性研究基于大型健康维护组织电子数据库,纳入2000-2019年诊断并接受抗甲状腺药物至少6个月的2-18岁儿童518例,随访至2024年。结果显示抗甲状腺药物疗程延长、初始甲巯咪唑剂量下降,根治性治疗减少,但未缓解率和复发率升高,总体缓解率31.1%。
要点
- 儿童甲亢管理趋向延长药物治疗、减少根治性治疗。
- 2010-2019年诊断者根治性治疗比例低于2000-2009年(27.5% vs 59.6%)。
- 总体缓解率31.1%,中位缓解时间2.36年。
核心结论
- 过去二十年儿童甲亢管理趋向更长期药物治疗和减少根治性治疗,此变化伴随复发率升高。
研究设计与样本
- 回顾性研究,使用大型健康维护组织电子数据库,纳入2000-2019年诊断的2-18岁儿童甲亢患者518例(75%女性),接受抗甲状腺药物至少6个月并随访至2024年。
主要发现
- 中位诊断年龄15.1(13.0-16.5)岁,中位随访10.4(6.5-15.1)年。
- 中位抗甲状腺药物治疗时长3.8(1.8-6.6)年。
- 平均初始甲巯咪唑剂量从2000-2009年的15.8(8.5-23.4)mg/天降至2010-2019年的12.9(7.3-19.4)mg/天(p=0.030)。
- 总体缓解率31.1%;2010-2019年诊断者根治性治疗比例低于2000-2009年(27.5% vs 59.6%,p<0.001),未缓解率(19.0% vs 3.8%,p<0.001)和复发率(15.9% vs 4.6%,p<0.001)更高。
- 161例缓解者中位缓解时间2.36年;较晚缓解与较小年龄(p=0.010)和抗甲状腺过氧化物酶阳性(p=0.018)相关,且晚缓解者基线游离甲状腺素水平更高(42.4 [26.7-61.5] vs 32.6 [24.4-42.5] pmol/L,p=0.014)。
临床怎么用
- 临床中应关注延长药物治疗策略可能伴随的复发风险升高,个体化评估根治性治疗时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over recent decades, variations have been observed in the incidence of pediatric hyperthyroidism (HT) and Graves' disease (GD), preferred treatment modalities, and long-term outcomes. This study aimed to evaluate trends and long-term outcomes of pediatric HT across a 20-year period in a large cohort. METHODS: We conducted a retrospective study using the electronic database of a large health maintenance organization. Children aged 2-18 years who were diagnosed with HT between 2000 and 2019, received antithyroid drugs (ATDs) for at least 6 months, and were followed up through 2024 were included in the analysis. RESULTS: Of 5,111,304 insured children, 518 (75% females) met the inclusion criteria. The median age at diagnosis was 15.1 (13.0-16.5) years, and the median follow-up was 10.4 (6.5-15.1) years. The median ATD treatment duration was 3.8 (1.8-6.6) years. The mean initial methimazole dose decreased from 15.8 (8.5-23.4) mg/day in 2000-2009 to 12.9 (7.3-19.4) mg/day in 2010-2019 (p = 0.030). The overall remission rate was 31.1%. Compared with children diagnosed in 2000-2009, those diagnosed in 2010-2019 were less likely to undergo definitive treatment (27.5% vs. 59.6%, p < 0.001) and had higher nonremission (19.0% vs. 3.8%, p < 0.001) and relapse rates (15.9% vs. 4.6%, p < 0.001). Among the 161 children achieving remission, the median time to remission was 2.36 years. Younger age and antithyroid peroxidase positivity were associated with later remission (p = 0.010 and p = 0.018, respectively). Higher baseline free thyroxine levels at diagnosis were found in children with late remission than in those with early remission (42.4 [26.7-61.5] vs. 32.6 [24.4-42.5] pmol/L, p = 0.014). CONCLUSIONS: Over the past two decades, the management of pediatric HT has evolved toward more prolonged medical therapy and decreased reliance on definitive treatments. This change in practice appears to coincide with an increased relapse rate, underscoring the clinical implications of these changes. Future studies should focus on evaluating the influence of these treatment strategies on the long-term prognosis of children with pediatric HT.
引用
- Oron T, Yackobovitch-Gavan M, Lazar L, et al. Trends in Management and Outcomes of Pediatric Hyperthyroidism Over Two Decades. Thyroid. 2026. PMID: 42347684. doi:10.1177/10507256261462523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。